309 related articles for article (PubMed ID: 14557452)
1. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm.
Clemmons DR; Chihara K; Freda PU; Ho KK; Klibanski A; Melmed S; Shalet SM; Strasburger CJ; Trainer PJ; Thorner MO
J Clin Endocrinol Metab; 2003 Oct; 88(10):4759-67. PubMed ID: 14557452
[TBL] [Abstract][Full Text] [Related]
2. How effective are current therapies for acromegaly?
Freda PU
Growth Horm IGF Res; 2003 Aug; 13 Suppl A():S144-51. PubMed ID: 12914744
[TBL] [Abstract][Full Text] [Related]
3. The place of pegvisomant in the acromegaly treatment algorithm.
Paisley AN; Trainer PJ; Drake WM
Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S101-6. PubMed ID: 15135788
[TBL] [Abstract][Full Text] [Related]
4. Cabergoline in acromegaly.
Kuhn E; Chanson P
Pituitary; 2017 Feb; 20(1):121-128. PubMed ID: 28025719
[TBL] [Abstract][Full Text] [Related]
5. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.
Tritos NA; Biller BM
Pituitary; 2017 Feb; 20(1):129-135. PubMed ID: 27631335
[TBL] [Abstract][Full Text] [Related]
6. Acromegaly: a new therapy.
Friend KE
Cancer Control; 2002; 9(3):232-5. PubMed ID: 12090246
[TBL] [Abstract][Full Text] [Related]
7. Role of medical therapy in the management of acromegaly.
Vance ML; Laws ER
Neurosurgery; 2005 May; 56(5):877-85; discussion 877-85. PubMed ID: 15854234
[TBL] [Abstract][Full Text] [Related]
8. Medical Treatment of Acromegaly with Dopamine Agonists or Somatostatin Analogs.
Chanson P
Neuroendocrinology; 2016; 103(1):50-8. PubMed ID: 25677539
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological approach to the treatment of acromegaly.
Ezzat S
Neurosurg Focus; 2004 Apr; 16(4):E3. PubMed ID: 15191332
[TBL] [Abstract][Full Text] [Related]
10. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
[TBL] [Abstract][Full Text] [Related]
11. Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy.
Frohman LA; Bonert V
Pituitary; 2007; 10(3):283-9. PubMed ID: 17534717
[TBL] [Abstract][Full Text] [Related]
12. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.
Herman-Bonert VS; Zib K; Scarlett JA; Melmed S
J Clin Endocrinol Metab; 2000 Aug; 85(8):2958-61. PubMed ID: 10946911
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic management of acromegaly].
Metzner C; Hadziselimovic S; Grafe I; Nawroth P; Kasperk C
Med Klin (Munich); 2006 Jan; 101(1):15-23. PubMed ID: 16418810
[TBL] [Abstract][Full Text] [Related]
14. Current and future medical treatments for patients with acromegaly.
Maffezzoni F; Formenti AM; Mazziotti G; Frara S; Giustina A
Expert Opin Pharmacother; 2016 Aug; 17(12):1631-42. PubMed ID: 27352098
[TBL] [Abstract][Full Text] [Related]
15. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal.
Parkinson C; Kassem M; Heickendorff L; Flyvbjerg A; Trainer PJ
J Clin Endocrinol Metab; 2003 Dec; 88(12):5650-5. PubMed ID: 14671148
[TBL] [Abstract][Full Text] [Related]
16. The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly.
Parkinson C; Whatmore AJ; Yates AP; Drake WM; Brabant G; Clayton PE; Trainer PJ
Clin Endocrinol (Oxf); 2003 Aug; 59(2):168-74. PubMed ID: 12864793
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
[TBL] [Abstract][Full Text] [Related]
19. Treatment of acromegaly.
Holdaway IM
Horm Res; 2004; 62 Suppl 3():79-92. PubMed ID: 15539805
[TBL] [Abstract][Full Text] [Related]
20. Current therapy and drug pipeline for the treatment of patients with acromegaly.
Kumar SS; Ayuk J; Murray RD
Adv Ther; 2009 Apr; 26(4):383-403. PubMed ID: 19444656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]